This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/domain/vavai/projekt/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/ontology/domain/vavai/
n12http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F68378050%3A_____%2F09%3A00334040%21RIV10-MSM-68378050/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F68378050%3A_____%2F09%3A00334040%21RIV10-MSM-68378050
rdf:type
skos:Concept n18:Vysledek
dcterms:description
TNF-related apoptosis-inducing ligand (TRAIL) is a proapoptotic cytokine implicated in cancer cell surveillance. Prolonged exposure of TRAIL-sensitive leukemia cell line HL60 cells to recombinant TRAIL or to cytostatic agents, cytarabine and idarubicin, resulted in the establishment of resistant subclones with distinct phenotypes. The TRAIL resistant subclones had decreased expression of TRAIL and TNFa death receptors, impaired activation of caspases 8 and 10 in response to TRAIL and TNFa and dysregulated expression of several apoptosis regulators. TRAIL resistant HL60 showed two phenotypes with different expression of CD14, osteoprotegerin, and several apoptosis regulators and were resistant to TNFa, suggesting disruption of the extrinsic apoptotic pathway. The concurrently derived cytarabine and idarubicin-resistant HL60 subclones remained sensitive to TRAIL-induced apoptosis. We identified distinct pathways for the development of HL60 leukemia cell resistance to apoptosis induction. TNF-related apoptosis-inducing ligand (TRAIL) is a proapoptotic cytokine implicated in cancer cell surveillance. Prolonged exposure of TRAIL-sensitive leukemia cell line HL60 cells to recombinant TRAIL or to cytostatic agents, cytarabine and idarubicin, resulted in the establishment of resistant subclones with distinct phenotypes. The TRAIL resistant subclones had decreased expression of TRAIL and TNFa death receptors, impaired activation of caspases 8 and 10 in response to TRAIL and TNFa and dysregulated expression of several apoptosis regulators. TRAIL resistant HL60 showed two phenotypes with different expression of CD14, osteoprotegerin, and several apoptosis regulators and were resistant to TNFa, suggesting disruption of the extrinsic apoptotic pathway. The concurrently derived cytarabine and idarubicin-resistant HL60 subclones remained sensitive to TRAIL-induced apoptosis. We identified distinct pathways for the development of HL60 leukemia cell resistance to apoptosis induction.
dcterms:title
TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine
skos:prefLabel
TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine
skos:notation
RIV/68378050:_____/09:00334040!RIV10-MSM-68378050
n3:aktivita
n5:Z n5:S n5:P
n3:aktivity
P(1M0506), P(LC06044), P(NR8317), S, Z(AV0Z50520514), Z(MSM0021620806), Z(MSM0021620808)
n3:cisloPeriodika
1
n3:dodaniDat
n13:2010
n3:domaciTvurceVysledku
n7:9022643
n3:druhVysledku
n9:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
346656
n3:idVysledku
RIV/68378050:_____/09:00334040
n3:jazykVysledku
n14:eng
n3:klicovaSlova
TRAIL resistance; leukemia; therapy
n3:klicoveSlovo
n4:leukemia n4:therapy n4:TRAIL%20resistance
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[7C5FF7CF4D5E]
n3:nazevZdroje
Blood Cells Molecules and Diseases
n3:obor
n11:EB
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
10
n3:projekt
n10:LC06044 n10:1M0506 n10:NR8317
n3:rokUplatneniVysledku
n13:2009
n3:svazekPeriodika
42
n3:tvurceVysledku
Simonova, T. Molinsky, J. Gašová, Z. Nečas, E. Čermák, J. Anděra, Ladislav Leahomschi, S. Doležalová, L. Živný, J. Klener, P. jr.
n3:wos
000262347900014
n3:zamer
n12:MSM0021620808 n12:MSM0021620806 n12:AV0Z50520514
s:issn
1079-9796
s:numberOfPages
8